EQUITY EXCHANGE RIGHT AGREEMENTEquity Exchange Right Agreement • July 6th, 2021 • Blend Labs, Inc. • Services-computer programming, data processing, etc. • Delaware
THIS EQUITY EXCHANGE RIGHT AGREEMENT (this “Agreement”) is made and entered into as of July , 2021, by and between Blend Labs Inc., a Delaware corporation (the “Company”), and Nima Ghamsari (the “Executive”).
EQUITY EXCHANGE RIGHT AGREEMENTEquity Exchange Right Agreement • April 12th, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS EQUITY EXCHANGE RIGHT AGREEMENT (THIS “AGREEMENT”) IS MADE AND ENTERED INTO AS OF , 2021, BY AND BETWEEN RECURSION PHARMACEUTICALS, INC., A DELAWARE CORPORATION (THE “COMPANY”), AND CHRISTOPHER GIBSON (THE “FOUNDER”).
EQUITY EXCHANGE RIGHT AGREEMENTEquity Exchange Right Agreement • March 1st, 2021 • Compass, Inc. • Services-computer programming services • Delaware
THIS EQUITY EXCHANGE RIGHT AGREEMENT (this “Agreement”) is made and entered into as of March __, 2021, by and between Compass, Inc., a Delaware corporation (the “Company”), and Robert Reffkin (the “Founder”).
EQUITY EXCHANGE RIGHT AGREEMENTEquity Exchange Right Agreement • March 22nd, 2024 • Ibotta, Inc. • Services-advertising • Delaware
THIS EQUITY EXCHANGE RIGHT AGREEMENT (this “Agreement”) is made and entered into as of __, 2024, by and between Ibotta, Inc., a Delaware corporation (the “Company”), and Bryan Leach (the “Founder”).
EQUITY EXCHANGE RIGHT AGREEMENTEquity Exchange Right Agreement • July 19th, 2021 • Robinhood Markets, Inc. • Security brokers, dealers & flotation companies • Delaware
THIS EQUITY EXCHANGE RIGHT AGREEMENT (this “Agreement”) is made and entered into as of , 2021, by and between Robinhood Markets, Inc., a Delaware corporation (the “Company”), and [NAME] (“Founder”). Each of the foregoing parties is referred to herein as a “Party” and collectively as the “Parties”.
EQUITY EXCHANGE RIGHT AGREEMENTEquity Exchange Right Agreement • May 12th, 2021 • Recursion Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS EQUITY EXCHANGE RIGHT AGREEMENT (this “Agreement”) is made and entered into as of April 20, 2021, by and between Recursion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Christopher Gibson (the “Founder”).
